EW - Edwards Lifesciences Corporation
179.00 -1.98 (-1.09%)
Pre-Market: 8:31AM EDT
| Previous Close | 178.27 |
| Open | 178.07 |
| Bid | 164.40 x 800 |
| Ask | 0.00 x 1800 |
| Day's Range | 177.27 - 182.18 |
| 52 Week Range | 123.00 - 197.86 |
| Volume | 1,502,762 |
| Avg. Volume | 1,293,129 |
| Market Cap | 37.664B |
| Beta (3Y Monthly) | 1.02 |
| PE Ratio (TTM) | 53.54 |
| EPS (TTM) | 3.38 |
| Earnings Date | Jul 24, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 191.60 |
- Investor's Business Daily•1 hour ago
Dow Jones Futures: Stock Market Rally At Tipping Point; 5 Big Earnings Movers
Stock futures were steady amid a wave of earnings from Snap, Texas Instruments, eBay, iRobot and more. Texas Instruments signaled that a chip downturn may last longer than expected.
- Investor's Business Daily•2 hours ago
Boston Scientific Earnings Miss Q1 Views, Thermo Fisher Tops
Boston Scientific earnings and sales missed Q1 estimates while Thermo Fisher earnings beat. Boston Scientific stock dipped while its fellow medical device maker edged higher.
- Thomson Reuters StreetEvents•7 hours ago
Edited Transcript of EW earnings conference call or presentation 23-Apr-19 9:00pm GMT
Q1 2019 Edwards Lifesciences Corp Earnings Call
Motley Fool•9 hours agoEdwards Lifesciences Corp (EW) Q1 2019 Earnings Call Transcript
EW earnings call for the period ending March 31, 2019.
- Investor's Business Daily•15 hours ago
This Medical Giant Beat Forecasts, But It's Losing Share In A Key Area
Medical device companies Edwards Lifesciences and Stryker topped first-quarter earnings expectations late Tuesday, though Stryker sales were just in line.
- Associated Press•16 hours ago
Edwards Lifesciences: 1Q Earnings Snapshot
On a per-share basis, the Irvine, California-based company said it had net income of $1.18. Earnings, adjusted for non-recurring costs, were $1.32 per share. The results beat Wall Street expectations. ...
- PR Newswire•16 hours ago
Edwards Lifesciences Reports First Quarter Results
IRVINE, Calif. , April 23, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...
- Simply Wall St.•21 hours ago
What You Must Know About Edwards Lifesciences Corporation's (NYSE:EW) Financial Health
Edwards Lifesciences Corporation (NYSE:EW), a large-cap worth US$37b, comes to mind for investors seeking a strong and reliable stock investment. Most investors favour these big stocks due to their strong balance sheet and high market...
- Benzinga•yesterday
The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) Moleculin Biotech Inc (NASDAQ: MBRX ) (announcement ...
- Investor's Business Daily•2 days ago
Earnings From Twitter, Lockheed And These Top Stocks: Action Plan
Twitter, Lockheed Martin, iRobot, Edwards Lifesciences and other top stocks report earnings on Tuesday. Here's a look at what to expect.
- Zacks•2 days ago
Edwards Lifesciences Takes Over CAS Medical Systems for $100M
This CASMED acquisition is expected to strengthen Edwards Lifesciences' (EW) critical care portfolio and expand its footprint in the smart monitoring technology market.
- PR Newswire•6 days ago
Edwards Lifesciences Completes Acquisition of CASMED
IRVINE, Calif., April 18, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced the completion of its acquisition of CAS Medical Systems, Inc. (CASM) (CASMED), a medical technology company dedicated to non-invasive brain and tissue oxygenation monitoring. Edwards announced in February that it had signed an agreement to acquire CASMED. Under the terms of the agreement, Edwards paid $2.45 in cash for each common share of CASMED, which equates to an equity value of approximately $100 million.
- Zacks•7 days ago
What's in Store for Edwards Lifesciences' (EW) Q1 Earnings?
Edwards Lifesciences (EW) expects to gain from core Critical Care product group in Q1.
- Zacks•8 days ago
Edwards Lifesciences (EW) Earnings Expected to Grow: Should You Buy?
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GuruFocus.com•9 days ago
David Rolfe Comments on Edwards Lifesciences
Edwards Lifesciences (NYSE:EW) is a top holding because we think there continues to be a multiyear runway for excellent top-line and bottom-line growth. Adjusted sales during the Company's fourth quarter grew +10%, driven by a +11% increase in transcatheter heart valve (THV) therapies. Edwards also released positive results of a highly anticipated trial that evaluated the performance of transcatheter aortic valve replacement (TAVR) in a previously unserved population.
- GuruFocus.com•9 days ago
David Rolfe's Wedgewood Partners 1st-Quarter 2019 Client Letter
Top first quarter performance detractors include Qualcomm, Berkshire Hathaway, Booking Holdings, Alphabet Class C, and Starbucks, plus Charles Schwab and C.H. Robinson. During the quarter we sold Qualcomm and trimmed positions in Ross Stores, Old Dominion Freight Line, and Charles Schwab.
- Simply Wall St.•15 days ago
Did The Underlying Business Drive Edwards Lifesciences's (NYSE:EW) Lovely 367% Share Price Gain?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Buying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly...
- PR Newswire•15 days ago
Edwards Lifesciences To Host Earnings Conference Call On April 23, 2019
IRVINE, Calif. , April 9, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...
- Motley Fool•19 days ago
Why Edwards Lifesciences Gained 13% in March
Positive clinical trial news lifted shares last month.
- Insider Monkey•27 days ago
Should You Avoid Edwards Lifesciences Corporation (EW)?
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
- Zacks•27 days ago
Can Retail Pharmacy USA Lift Walgreens' (WBA) Q2 Earnings?
Widening pharmacy network, healthy prescription volumes along with contributions from Rite Aid are expected to contribute to Walgreens Boots' (WBA) top line in the fiscal second quarter.
- Simply Wall St.•29 days ago
Do Directors Own Edwards Lifesciences Corporation (NYSE:EW) Shares?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to know who really controls Edwards LifesciencesRead More...
- Zacks•last month
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
Style Box ETF report for JHMM
- Zacks•last month
Edwards Lifesciences Presents Positive Partner 3 Trial Data
Edwards Lifesciences (EW) expects SAPIEN 3 to gain FDA approval for the low-risk indication in late-2019.
